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The epidermal growth factor (EGF)-receptor ligand amphiregulin
(AREG) is a potent growth factor implicated in proliferative skin diseases
and in primary and metastatic epithelial cancers. AREG, synthesized as a
propeptide, requires conversion to an active peptide by metalloproteases
by a process known as ectodomain shedding. Although (ADAM17) a
disintegrin and metalloprotease 17 is a key sheddase of AREG, ADAM8-,
ADAM15-, and batimastat (broad metalloprotease inhibitor)-sensitive met-
alloproteases have also been implicated in AREG shedding. In the pre-
sent study, using a curly bare (Rhbdf2cub) mouse model that shows loss-
of-hair, enlarged sebaceous gland, and rapid cutaneous wound-healing
phenotypes mediated by enhanced Areg mRNA and protein levels, we
sought to identify the principal ectodomain sheddase of AREG. To this
end, we generated Rhbdf2cub mice lacking ADAM17 specifically in the
skin and examined the above phenotypes of Rhbdf2cub mice. We find that
ADAM17 deficiency in the skin of Rhbdf2cub mice restores a full hair
coat, prevents sebaceous gland enlargement, and impairs the rapid
wound-healing phenotype observed in Rhbdf2cub mice. Furthermore,
in vitro, stimulated shedding of AREG is abolished in Rhbdf2cub mouse
embryonic keratinocytes lacking ADAM17. Thus, our data support
previous findings demonstrating that ADAM17 is the major ectodomain
sheddase of AREG.
The epidermal growth factor receptor (EGFR) path-
way plays a major role in normal development, and in
multiple diseases including epithelial cancers and
chronic obstructive pulmonary disease, and in liver
diseases [1–5]. A critical step in regulating this path-
way is ectodomain shedding of type 1 transmembrane
EGFR ligands from the cell surface by membrane-
anchored metalloproteases [6]. For instance, type-1
transmembrane EGFR ligands, including amphiregulin
(AREG), transforming growth factor alpha (TGFa),
epidermal growth factor (EGF), and heparin-binding
EGF (HB-EGF), are produced as inactive propeptides.
In the ectodomain shedding process, ADAMs (a
disintegrin and metalloproteases) cleave propeptides to
release soluble peptides, leading to activation of the
EGFR signaling pathway [7,8].
Among the multiple ADAMs studied (ADAM8,
ADAM9, ADAM10, ADAM12, ADAM15, ADAM17,
and ADAM19), ADAM10 and ADAM17 have
emerged as key sheddases of the EGFR ligands EGF,
betacellulin, HB-EGF, and TGFA [9,10]. In culture,
ectodomain shedding assays using mouse embryonic
fibroblasts (mEFs) lacking ADAM10 or ADAM17
show impaired shedding of EGF and betacellulin, and
HB-EGF or TGFA, respectively [11]. In line with
these findings, ADAM17 knockout mice show defects
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in cardiac valve and eyelid development [8,12], defects
that are also observed in mice deficient in HB-EGF
(Hbegf/ mice) and in TGFA (Tgfa/ mice), respec-
tively [12–14]. Furthermore, using loss-of-function
experiments in mEFs, Sahin et al. [9] demonstrated
that both constitutive shedding and stimulated ectodo-
main shedding of EGFR ligands, including EGF,
epiregulin, betacellulin, HB-EGF, TGFA, and AREG,
are unaltered in the absence of ADAM8, ADAM9,
ADAM12, ADAM15, and ADAM19. Thus, substan-
tial literature suggests that ADAM10 and ADAM17
have essential, but distinct, roles in shedding of EGFR
ligands.
Results of in vivo studies implicate ADAM17 as the
specific metalloprotease contributing to the ectodo-
main shedding of AREG [15], a potent growth factor
implicated in proliferative skin diseases, and primary
and metastatic epithelial cancers [16–18]. Moreover,
results of in vitro studies have suggested ADAM17 as
a key sheddase [9,10]; nevertheless, ADAM8-,
ADAM15-, and batimastat (broad metalloprotease
inhibitor)-sensitive metalloproteases have also been
implicated in AREG shedding in vitro [11]. Under-
standing of the sheddase mechanisms for AREG is
critical for development of more effective therapies for
diseases associated with this growth factor.
To determine whether ADAM17 is the key shed-
dase of AREG, we utilized the curly bare (Rhbdf2cub)
gain-of-function mouse mutation. Homozygosity for
this spontaneous mutation in the Rhbdf2 gene aug-
ments Areg mRNA and protein levels and results in
alopecia, sebaceous gland enlargement, and rapid
wound-healing phenotypes through enhanced secre-
tion of AREG and subsequent hyperactivation of the
EGFR pathway [19]. Furthermore, AREG deficiency
in Rhbdf2cub/cub mice prevents the alopecia, sebaceous
gland enlargement, and rapid wound-healing pheno-
types, suggesting that AREG is the primary mediator
of the Rhbdf2cub phenotype [19]. Thus, the Rhbdf2cub
mouse mutation provides a powerful in vivo model
system that allows us to examine the physiological
role of ADAM17 in ectodomain shedding of AREG
and in AREG-mediated downstream events, including
wound healing.
Here, we demonstrate that conditional deletion of
ADAM17 in the skin of Rhbdf2cub/cub mice impairs the
AREG-mediated hair, sebaceous gland, and wound-
healing phenotypes observed in these mice. We also
demonstrate that ADAM17 deficiency significantly
abolishes both stimulated and unstimulated shedding
of AREG in Rhbdf2cub/cub mouse embryonic ker-
atinocytes (MEKs), suggesting that ADAM17 is indis-
pensible for sheddase of AREG.
Materials and methods
Animals
All animal work conformed to regulations in the Guide for
the Care And Use of Laboratory Animals (Institute of
Laboratory Animal Resources, National Research Council,
National Academy of Sciences, 8th edition, 2011). Euthana-
sia was performed in a manner consistent with the 2013
recommendations of the American Veterinary Medical
Association (AVMA) Guidelines on Euthanasia. All indi-
viduals working with animals in this project read and
adhered to The Jackson Laboratory policy, POL.AWC.025
Euthanasia in Animal Experiments Involving Pain, Dis-
tress, or Illness. The Rhbdf2cub/cub, Rhbdf2/, and Rhbd-
f2cub/cub Areg/ mice are maintained on the C57BL/6J
genetic background, and Adam17flox/flox and Adam17flox/flox
K14-Cre mice are of mixed genetic background [20]. We
generated Rhbdf2cub/cub Adam17flox/flox K14-Cre mice by
crossing female Rhbdf2+/cub, Adam17+/flox, K14-Cre mice
with male Rhbdf2cub/cub, Adam17flox/flox mice. AregMcub/Mcub
mice are referred to as Areg/ mice in this manuscript
[19]. Mice were maintained under modified barrier condi-
tions on a 12-h light and 12-h dark cycle with constant
temperature and humidity. The Animal Care and Use
Committee at The Jackson Laboratory approved all of the
experimental procedures.
Histology
Mice were euthanized by CO2 asphyxiation followed by
open chest necropsy, a secondary method of euthanasia.
Dorsal skin was removed, fixed in 10% neutral buffered
formalin for 24 h, processed routinely, embedded in paraf-
fin, sectioned and stained, with hematoxylin and eosin
(H&E).
Isolation of primary keratinocytes
For isolation of MEKs, skin from embryonic day 18 mouse
embryos was incubated overnight in neutral protease at
4 °C. Following separation of the epidermis from the dermis,
the epidermis was placed in Petri dishes containing trypsin
(#12563029; ThermoFisher Scientific, Waltham, MA, USA)
and allowed to incubate for 30 min at room temperature.
After blocking trypsin activity with soybean trypsin inhibitor
(#R007100; ThermoFisher Scientific), cells were grown in
KBM-2 medium (#CC-3107; Lonza, Fisher Scientific, Pitts-
burgh, PA, USA) supplemented with antibiotic/antimycotic.
Measurement of amphiregulin protein levels
AREG levels in the cell culture supernatant were measured
via ELISA as described previously [19]. Briefly, 100 lL of cell
culture supernatant was added to capture antibody-precoated
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plates and incubated for 2 h at room temperature (RT).
After three washes, 100 lL of the detection antibody was
added to each well and incubated for an additional 2 h at
RT. Following three washes, 100 lL of streptavidin/HRP
was added to each well and incubated at RT for 20 min,
before adding 100 lL of substrate solution (20 min incuba-
tion) and 50 lL of stop solution. A spectrophotometer
(SpectraMax 190; Molecular Devices, San Jose, CA, USA)
was used to determine the optical density.
Statistical analysis
One-way ANOVA and two-way ANOVA were used for
comparison of several groups using PRISM v7 software
(GraphPad, La Jolla, CA, USA). A P < 0.05 was consid-
ered statistically significant. Data represent mean  SD.
Results
The loss-of-hair, enlarged sebaceous gland, and
rapid wound-healing phenotypes of Rhbdf2cub
mice are mediated through ADAM17
To determine whether ADAM17 is essential for the
loss-of-hair and enlarged sebaceous gland phenotypes
exhibited by Rhbdf2cub/cub mice, we generated Rhbd-
f2cub/cub mice lacking ADAM17 in skin, by crossing
Rhbdf2cub/cub mice with Adam17flox/flox K14-Cre mice,
and studied the phenotypes of second-generation off-
spring. We noted that ADAM17 acts as a genetic
modifier of Rhbdf2cub/cub mice – Rhbdf2cub/cub
Adam17flox/flox K14-Cre mice display a full hair coat,
in contrast to the complete hair loss in Rhbdf2cub/cub
mice (Fig. 1A). We next performed histopathological
examination of truncal skin from Rhbdf2cub/cub
(Fig. 1B.a,b) and Rhbdf2cub/cub Adam17flox/flox K14-
Cre (Fig. 1B.c,d) mice at 3 weeks of age. Although,
gross examination of Rhbdf2cub/cub Adam17flox/flox
K14-Cre mice showed a full hair coat (Fig. 1A, 3),
histological examination revealed mild follicular dys-
trophy (arrowhead) in Rhbdf2cub/cub Adam17flox/flox
K14-Cre mice compared with extreme follicular dystro-
phy in Rhbdf2cub/cub mice (arrows). Additionally, mice
of both strains exhibited hyperkeratosis (H) and thick-
ened epidermis (E), whereas enlargement of sebaceous
glands (*) was observed only in Rhbdf2cub/cub mice,
suggesting that deletion of ADAM17 partially reverses
the loss-of-hair and sebaceous gland phenotypes of
Rhbdf2cub/cub mice.
We next examined the rapid wound-healing pheno-
type of Rhbdf2cub/cub mice. The Rhbdf2cub mutation
induces a rapid wound-healing phenotype through
enhanced secretion of AREG [19,21]; when we
punched 2-mm through-and-through holes in the ear
pinnae of Rhbdf2cub/cub mice, within 2 weeks ear-hole
closure of more than 90% was observed in Rhbdf2cub/cub
mice, in contrast to approximately 20% ear-hole closure
in Rhbdf2+/+ mice [19]. Here, we wanted to determine
whether the wound-healing phenotype in Rhbdf2cub/cub
mice requires ADAM17. Using the above-mentioned
ear-hole closure assay, we tested the wound-healing phe-
notype of Rhbdf2cub/cub Adam17flox/flox K14-Cre mice and
compared it to those of Adam17flox/flox K14-Cre and
Rhbdf2cub/cub mice. Not surprisingly, impairment of
wound healing was similar in Adam17flox/flox K14-Cre
mice (Fig. 1C, left column) and Rhbdf2cub/cub
Adam17flox/flox K14-Cre mice (Fig. 1C, middle column),
whereas Rhbdf2cub/cub mice showed the rapid wound-
healing phenotype (Fig. 1C, right column). Collectively,
these data suggest that loss of ADAM17 in the skin of
Rhbdf2cub/cub mice modifies the loss-of-hair phenotype
and restores a full hair coat and diminishes the wound-
healing phenotype.
Loss of ADAM17 specifically in the skin causes
dermatitis and myeloproliferative disease in
Rhbdf2cub/cub mice
A previous study showed that sustained deficiency of
ADAM17 in the epidermis of wild-type mice results in
epidermal barrier defects, and subsequently dermatitis
and myeloproliferative disease; that is, a significant
increase in the myeloid-cell infiltration [20]. Thus, to
determine whether ADAM17 deficiency also causes
dermatitis in Rhbdf2cub/cub mice, we examined the skin
phenotype of Rhbdf2cub/cub ADAM17flox/flox K14-Cre
mice in comparison with that of ADAM17flox/flox K14-
Cre and ADAM17flox/flox control mice. The skin of
Rhbdf2cub/cub ADAM17flox/flox K14-Cre mice displayed
noticeable scaling (Fig. 2A, left), indistinguishable
from the phenotype of ADAM17flox/flox K14-Cre mice
(Fig. 2A, right). Furthermore, histological examination
of H&E sections revealed a thicker hypodermis (H)
and a thinner dermis (D) in ADAM17flox/flox control
mice (Fig. 2B.a) in contrast to a thinner hypodermis
and a thicker dermis in both ADAM17flox/flox K14-Cre
(Fig. 2B.b) and Rhbdf2cub/cub ADAM17flox/flox K14-Cre
(Fig. 2B.c) mice. Additionally, we observed epidermal
thickening (asterisk), hyperkeratosis (arrow head), and
considerable infiltration of inflammatory cells, includ-
ing macrophages and neutrophils (arrows), in the der-
mis of ADAM17flox/flox K14-Cre mice (Fig. 2B.e) and
Rhbdf2cub/cub ADAM17flox/flox K14-Cre mice
(Fig. 2B.f), in contrast to ADAM17flox/flox control mice
(Fig. 2B.d), which did not manifest any indication of
skin disease.
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Next, using flow cytometry analyses we determined
whether there was any indication of myeloproliferative
disease in Rhbdf2cub/cub Adam17flox/flox K14-Cre mice
by quantifying the differences in the percentages of
splenic macrophages (Fig. 2C, top panel) and neutrophils
(Fig. 2C, bottom panel) between ADAM17flox/flox
K14-Cre and Rhbdf2cub/cub ADAM17flox/flox K14-Cremice.
Compared with control mice (ADAM17flox/flox and
ADAM17flox/+ mice), we observed significantly higher
percentages of macrophages and neutrophils in both of
ADAM17flox/flox K14-Cre and Rhbdf2cub/cub Adam17flox/flox
K14-Cre mice, suggesting that loss of ADAM17 specifi-
cally in the skin results in considerable myeloproliferation
in Rhbdf2cub/cub mice. Taken together, our results indicate
that lack of ADAM17 in the skin results in dermatitis and
myeloproliferative disease, which validates previous find-
ings by Franzke et al. [20] that ADAM17 maintains the
skin barrier. Moreover, our results showing development
of a similar overt skin phenotype observed by Franzke
et al. and restoration of hair growth in Rhbdf2cub/cub mice
lacking ADAM17 implicate ADAM17 as a participant in
ectodomain shedding of AREG.
Ectodomain shedding of AREG requires ADAM17
To determine whether ADAM17 is required for
AREG ectodomain shedding, we asked whether loss of






Fig. 1. (A) Conditional deletion of ADAM17 in the skin of Rhbdf2cub/cub mice restores hair growth. Also, note the relatively smaller size of
the Rhbdf2cub/cub ADAM17flox/flox K14-Cre (3) and ADAM17flox/flox K14-Cre (1) mice compared with Rhbdf2cub/cub (2) mice. (B) (a, b) Truncal
skin sections of Rhbdf2cub/cub mice (2) displaying extreme follicular dystrophy (arrow), thickened epidermis (E), enlarged sebaceous glands
(*), and hyperkeratosis (H). (c, d) Although Rhbdf2cub/cub ADAM17flox/flox K14-Cre mice exhibit a full hair coat, histological analysis of truncal
skin sections of Rhbdf2cub/cub ADAM17flox/flox K14-Cre mice (3) revealed mild follicular dystrophy (arrow heads); however, there was no
evidence of sebaceous gland hyperplasia (★). Scale bars: 250 lm (a, c) and 50 lm (b, d). (C) Healing of ear tissue in 6- to 8-week-old female
ADAM17flox/flox K14-Cre (1), Rhbdf2cub ADAM17flox/flox K14-Cre (3), and Rhbdf2cub/cub (2) mice (n = 3 per group; representative images are
shown) at 0 and 14 days postwounding. Magnification = 49; Scale bars = 1 mm; Quantification of ear-hole closures on day 14;
***P < 0.001.
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secretion with or without stimulation with 100 nM
phorbol-12-myristate-13-acetate (PMA). We also
examined AREG-stimulated and AREG-unstimulated
secretion in Rhbdf2+/+, Rhbdf2cub/cub Areg/, and
Rhbdf2/ keratinocytes, for comparison. First, in line
with our previous findings [19], we found that both the
stimulated secretion (red column) and unstimulated
(blue column) secretion of AREG are significantly
increased in Rhbdf2cub/cub keratinocytes compared with
control keratinocytes (Fig. 3A; 1, Rhbdf2+/+; 2, Rhbd-
f2cub/cub). Additionally, because Rhbdf2cub/cub Areg/
mice do not produce a functional AREG protein [19],
as expected, there was no detectable AREG in the cul-
ture supernatants of Rhbdf2cub/cub Areg/ ker-
atinocytes (Fig. 3A; 3). Furthermore, there was a
significant reduction in AREG levels in the culture
supernatants of Rhbdf2/ keratinocytes with or with-
out stimulation in comparison with those of Rhbdf2+/+
and Rhbdf2cub/cub keratinocytes (Fig. 3A; 4), suggesting
that RHBDF2 is required for both stimulated and
unstimulated shedding of AREG.
Second, we observed that, compared to control
Rhbdf2+/+ keratinocytes, keratinocytes lacking
ADAM17 showed approximately 85% and 75% lower
AREG levels in stimulated and unstimulated condi-
tions, respectively (Fig. 3A; 5, Adam17flox/flox K14-
Cre). Moreover, there was no significant difference in
AREG levels between stimulated and unstimulated
conditions in Adam17flox/flox K14-Cre keratinocytes






Fig. 2. (A) The role of ADAM17 in regulating the skin barrier has been established previously [20] – deletion of ADAM17 in the skin results
in epidermal defects and dermatitis. A similar phenotype – dry scaly skin (arrows) – was observed in both Adam17flox/flox K14-Cre (1) and
Rhbdf2cub/cub Adam17flox/flox K14-Cre (2) mice. (B) Deletion of ADAM17 in the skin results in epidermal defects and dermatitis. A similar
dermatitis-like phenotype, including epidermal thickening (asterisk), hyperkeratosis (arrow head), and considerable infiltration of inflammatory
cells (arrows), was observed in both Adam17flox/flox K14-Cre (b, e) and Rhbdf2cub/cub Adam17flox/flox K14-Cre (c, f) mice, compared to the
normal skin in Adam17 flox/flox control mice (a, d). Note the relatively thicker dermis (D) and thinner hypodermis (H) in both Adam17flox/flox
K14-Cre (b) and Rhbdf2cub/cub Adam17flox/flox K14-Cre (c) mice, compared to the thinner dermis and thicker hypodermis in Adam17flox/flox
control mice (a). Scale bars: 250 lm (low magnification) and 50 lm (high magnification). (C) Both ADAM17flox/flox K14-Cre and Rhbdf2cub/cub
ADAM17flox/flox K14-Cre mice develop myeloproliferative disease, evidenced by the increased percentage of macrophages (top) and
neutrophils (bottom) in the spleens of these mice compared with control mice (ADAM17flox/flox and ADAM17flox/+ mice).
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hair growth and loss of rapid wound-healing pheno-
types in Rhbdf2cub/cub Adam17flox/flox K14-Cre mice, we
observed that Rhbdf2cub/cub Adam17flox/flox K14-Cre
keratinocytes failed to secrete AREG even after stimu-
lation with PMA (Fig. 3A; 6), in contrast to a signifi-
cant increase in both stimulated and unstimulated
Rhbdf2cub/cub keratinocytes (Fig. 3A; 2), suggesting
that the Rhbdf2cub mutation fails to promote AREG
secretion in the absence of ADAM17. Notably, the
levels of AREG observed in keratinocytes lacking
ADAM17 (Fig. 3A; 5 and 6) can be attributed to con-
stitutive shedding, which does not require ectodomain
shedding by metalloproteases [9].
Fourth, similar results were obtained when ker-
atinocytes isolated from the aforementioned strains (1
through 6) of mice were exposed to bacterial endo-
toxin lipopolysaccharide (LPS) and assayed for AREG
levels in the culture supernatants (Fig. 3B). Interest-
ingly, there was a subtle but significant increase in the
levels of AREG in Adam17flox/flox K14-Cre and Rhbd-
f2cub/cub Adam17flox/flox K14-Cre keratinocytes upon
stimulation with LPS (Fig. 3B; 5 and 6); however, this
could be due to differential regulation of AREG con-
stitutive shedding by PMA versus LPS. Taken
together, because loss of ADAM17 significantly abol-
ished stimulated secretion of AREG in Rhbdf2cub/cub
keratinocytes, these data strongly suggest that
ADAM17 is essential for ectodomain shedding of
AREG (Fig. 3C).
Discussion
Amphiregulin plays an important role in pathological
processes, including psoriasis induction [22,23], cancer
progression, and resistance to chemotherapy and anti-
EGFR therapies [16,24]. For example, AREG has
been characterized as a multicrine – autocrine, para-
crine, and endocrine (systemic) – growth factor in pri-
mary and metastatic epithelial cancers [25–27]. AREG
induces its own expression to enable self-sufficiency of
growth signals acting through EGFR, via an extracel-
lular autocrine loop [28], suggesting that dysregulation
of this loop could lead to overexpression of AREG.
Additionally, cancer cells overexpressing AREG can
induce neoplastic transformation of neighboring cells
through paracrine or endocrine activity [15]. Also,
more recently, we showed in mice that AREG under-
lies the hyperproliferative skin disease tylosis and that
Fig. 3. (A) ELISA quantitation of cleaved AREG from the supernatant of MEKs after overnight stimulation with either DMSO or 100 nM
PMA. ND, not detected; Data represent mean  SD. ****P < 0.0001; ns, not significant. (B) ELISA quantitation of cleaved AREG from the
supernatant of MEKs after overnight stimulation with either PBS or 1 lgmL1 LPS. ND, not detected; Data represent mean  SD.
****P < 0.0001; ***P < 0.001; **P < 0.01; ns, not significant. (C) Loss of ADAM17 modifies the Rhbdf2cub/cub hair loss and ear-punch
closure phenotypes and in vitro deficiency of ADAM17 in Rhbdf2cub/cub keratinocytes prevents stimulated secretion of AREG, together
suggesting that ADAM17 is indispensible for sheddase of AREG.
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loss of AREG restores the normal skin phenotype in a
mouse model of human tylosis [29]. Together, these
studies highlight the key role of AREG in several
pathological processes, and the potential of AREG
depletion as a therapeutic approach in multiple dis-
eases. To develop effective therapeutic strategies tar-
geting AREG, it is important to understand how
AREG secretion is regulated in vivo.
Amphiregulin synthesized as pro-AREG is con-
verted to an active form by metalloproteases.
Although several ADAMs have been implicated, a
study by Sahin et al. [9] showed that Adam17/
MEFs exhibit impaired shedding of AREG, indicating
that ADAM17 may be a major sheddase. Comparison
of the phenotype of Adam17/ mice with that of
Areg/ mice is a potential means of providing sup-
port for a role of ADAM17 as the major sheddase of
AREG. However, literature suggests that in contrast
to Hbegf/ and Tgfa/ mice [13,14], Areg/ mice
are viable and do not present with an overt phenotype,
except for defects in mammary gland development
during puberty and in nursing [30]. Thus, it remains to
be determined whether the phenotype of mice with
Areg depletion resembles any aspects of the Adam17/
 phenotype. Adam17/ mice exhibit perinatal lethal-
ity, limiting the ability to examine mammary gland
development and nursing competence phenotypes. Fur-
thermore, although at birth Adam17/ pups exhibit
stunted growth and development [31], including defec-
tive mammary branching, suggesting a role for
ADAM17 in shedding of AREG, there is a lack of
direct evidence. In the present study, using mouse
genetics and in vitro ectodomain shedding assays, we
sought to determine whether loss of ADAM17 abol-
ishes shedding of AREG in vivo. We demonstrate that
loss of ADAM17 impairs the AREG-mediated loss-of-
hair, enlarged sebaceous gland, and rapid wound-heal-
ing phenotypes observed in Rhbdf2cub/cub mice. More-
over, we find that conditional deletion of ADAM17 in
the skin of Rhbdf2cub/cub mice significantly inhibits
stimulated secretion of AREG in keratinocytes, sug-
gesting that ADAM17 is necessary for ectodomain
shedding of AREG in keratinocytes. Notably, in
macrophages, RHBDF2 also regulates stimulated
secretion of pro-inflammatory cytokine tumor necrosis
factor alpha (TNFa) through ADAM17 [32,33], impli-
cating that, similar to ectodomain shedding of AREG,
ADAM17 might be key for shedding of RHBDF2-
mediated secretion of TNFa. Consistently, RHBDF2
has recently been suggested to be an essential regulator
of stimulated growth factor and cytokine signaling via
ADAM17 [34,35].
We previously observed that Rhbdf2 gain-of-func-
tion alleles, including Rhbdf2cub, could induce secretion
of AREG in the presence of a potent ADAM17 inhibi-
tor marimastat [19]. Moreover, both our group [19]
and Siggs et al. [36] observed that ADAM17 activity is
reduced in Rhbdf2cub/cub mice. Based on these findings,
we postulated that RHBDF2 might regulate secretion
of AREG independent of ADAM17 activity [19].
However, results from the present study showing that
loss of ADAM17 reverses the phenotype of Rhbdf2cub/
cub mice suggest that ADAM17 is indispensible for
sheddase of AREG and that RHBDF2 does not act as
a sheddase of AREG.
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